The concept of "next best action" (NBA) has been part of pharmaceutical marketing vocabulary for over a decade, but the practical reality of implementing it has undergone a fundamental transformation. What was once a manual exercise in segment-based content sequencing has become an AI-driven, real-time recommendation engine that analyzes hundreds of signals per HCP to determine the optimal channel, content, timing, and frequency for every interaction. The brands that have successfully deployed NBA are seeing measurable improvements in HCP engagement, prescribing conversion, and marketing efficiency that were not possible with traditional rule-based approaches.
This article explains how AI-powered NBA systems work in pharmaceutical marketing, the data inputs they require, the model architectures that power them, and a maturity framework for assessing where your team stands and what the next step looks like.
What is Next Best Action in Pharma?
At its core, NBA is a decisioning framework that answers a deceptively simple question: given everything we know about a specific HCP right now, what should we do next to maximize the probability of a desired business outcome? The "what" encompasses four dimensions simultaneously:
- Channel: Should we send an approved email, schedule a rep visit, invite to a webinar, serve a digital ad, or trigger a sample delivery?
- Content: Which specific message, clinical dataset, or piece of content will resonate most with this HCP based on their current knowledge state and interests?
- Timing: When is the optimal moment to execute this action? Next Tuesday morning? After the next anticipated patient encounter? Immediately following a competitor's formulary change?
- Frequency: How many times should we attempt contact through this channel before switching? What is the optimal cadence for this particular HCP?
Traditional marketing operations teams make these decisions using a combination of segmentation rules, pre-defined cadences, and rep discretion. A typical approach might be: "For high-value cardiologists who have prescribed once but not reached three TRx, send email sequence A, followed by a rep call within 14 days, then invite to the cardiology webinar." This is a static, segment-based approach that treats all HCPs within a segment identically.
AI-powered NBA replaces this static logic with dynamic, individual-level recommendations that continuously update based on real-time behavioral signals. Instead of asking "what do cardiologists in this segment need next?" the system asks "what does Dr. Smith specifically need right now, given her unique engagement history, prescribing trajectory, and recent behavioral signals?"
The Performance Gap: Brands that have implemented AI-powered NBA report 20-35% improvement in HCP engagement rates, 15-25% increase in new prescriber conversion, and 10-18% improvement in marketing ROI compared to traditional rule-based cadences. These improvements come not from spending more, but from spending smarter, directing each interaction to the right HCP through the right channel at the right time.
The Data Foundation: What NBA Models Need
NBA models are only as good as the data that feeds them. The most sophisticated algorithm in the world will produce poor recommendations if it lacks the behavioral signals needed to understand where each HCP is in their decision journey and what will move them forward. Here are the critical data inputs, organized by category.
Prescription and Claims Data
Prescription data is the most important outcome signal for NBA models. It tells the model whether its past recommendations are working and provides the ground truth for training future recommendations.
- TRx and NRx trends: Weekly or monthly prescription volumes at the individual HCP level, sourced from IQVIA Xponent or similar providers. The model uses trajectory (accelerating, stable, declining) as a key feature.
- Market share: The HCP's share of prescriptions for your brand versus competitors within the therapeutic class. A declining share may trigger a different NBA than a stable share.
- Claims data: Patient-level diagnosis and procedure codes (where available) that indicate the HCP's patient mix and help predict future prescribing needs. For example, an increase in newly diagnosed Type 2 diabetes patients for an endocrinologist signals an upcoming prescribing opportunity.
CRM and Field Activity Data
Veeva CRM and similar platforms capture the richest behavioral data about HCP interactions in the field.
- Call activity: Rep visit frequency, call duration, call quality ratings, and call outcomes. An HCP who has been detailed three times in the past month with high-quality calls is in a very different journey stage than one who has not seen a rep in 90 days.
- Access status: Whether the HCP is accessible to reps (full access, partial access, no see). Access status fundamentally changes the available channel set and the NBA recommendation.
- Samples distributed: Sample delivery and acknowledgment data. Sample requests are a strong signal of clinical interest and trial intent.
- Call notes (NLP-enriched): Advanced NBA systems use natural language processing to extract topics, sentiments, and objections from rep call notes, adding qualitative richness to the behavioral profile.
Digital Engagement Data
Digital channels generate granular, timestamped engagement data that provides high-resolution signals about HCP interests and knowledge state.
- Approved email: Opens, clicks, click-through rates, time spent reading, and content-level engagement. An HCP who clicks on a link about safety data is signaling a different information need than one who clicks on efficacy data.
- Website behavior: Page visits, content downloads, time on page, and navigation paths on your brand's HCP portal. These reveal the specific clinical topics the HCP is researching.
- Webinar participation: Registration, attendance duration, Q&A participation, and poll responses. Full attendance with active Q&A is a much stronger engagement signal than registration without attendance.
- Programmatic advertising: Impression delivery, viewability, click-through rates, and frequency at the HCP level (where NPI matching is available).
External Context Signals
Sophisticated NBA models also incorporate external data that affects prescribing behavior independently of marketing.
- Formulary changes: Health plan and PBM formulary updates that affect patient access and copay burden. A favorable formulary win should trigger intensified outreach to HCPs who previously cited access as a barrier.
- Competitor activity: Launches, label changes, or safety events for competing products. A competitor's safety alert creates an opening for your brand's messaging.
- Congress calendar: Upcoming medical meetings where your brand has a presence. NBA can pre-schedule outreach to maximize impact around key data presentations.
- Seasonal patterns: Diagnosis and prescribing cycles tied to seasons (allergy season, flu season) or healthcare system patterns (beginning of plan year, deductible reset).
NBA Model Architectures
There are three primary model architectures used for NBA in pharmaceutical marketing, each with different complexity levels, data requirements, and output characteristics.
1. Rule-Based NBA (Baseline)
Rule-based NBA uses pre-defined decision trees that map HCP segments to recommended next actions. The rules are typically developed by brand teams based on clinical expertise and historical performance data.
Example: "If HCP is a high-prescriber with declining TRx trend, and last rep call was >30 days ago, and email open rate < 20%, recommend: schedule rep visit with competitive displacement messaging within 7 days."
Strengths: Transparent and explainable. Easy to implement and modify. Aligns with clinical expertise and brand strategy. Low data requirements.
Weaknesses: Static and segment-based rather than individualized. Cannot discover patterns that humans have not anticipated. Does not learn or improve over time. Scales poorly as the number of segments and channels grows.
2. Collaborative Filtering and Similarity-Based NBA
Collaborative filtering identifies HCPs with similar behavioral profiles and recommends actions that worked well for similar physicians. This is the same approach that powers product recommendations in e-commerce, adapted for pharmaceutical marketing.
How it works: The model creates an HCP similarity matrix based on prescribing patterns, engagement behavior, specialty, practice setting, and demographic attributes. For each HCP, it identifies the "nearest neighbors" (the 50-200 most similar HCPs) and recommends the channel-content combinations that produced the best outcomes for those neighbors.
Strengths: Individualized recommendations without requiring explicit rules. Can discover non-obvious patterns in the data. Relatively straightforward to implement with existing data infrastructure.
Weaknesses: Cold-start problem: new HCPs with limited behavioral history receive poor recommendations. Limited ability to optimize for long-term outcomes. Does not account for causal relationships between actions and outcomes (correlation-based rather than causal).
3. Reinforcement Learning NBA (Advanced)
Reinforcement learning (RL) is the most sophisticated NBA architecture and the approach most likely to deliver transformative results. An RL agent learns the optimal action policy by continuously interacting with the environment (HCPs across channels) and receiving feedback in the form of engagement and prescribing outcomes.
How it works: The RL framework models the NBA problem as a Markov Decision Process. Each HCP has a "state" (their current engagement profile, prescribing trajectory, and recent interactions). The agent selects an "action" (which channel and content to deploy next). The environment returns a "reward" (engagement metrics in the short term, prescribing outcomes in the medium term). The agent updates its policy to maximize cumulative long-term reward.
Strengths: Optimizes for long-term outcomes rather than immediate clicks or opens. Continuously learns and adapts from feedback. Can discover non-obvious channel sequences and timing patterns. Handles the sequential nature of HCP engagement (the optimal action today depends on what happened in prior interactions).
Weaknesses: Requires significant data volume (typically 12-24 months of unified interaction data across thousands of HCPs). Complex to implement and requires specialized data science talent. The "exploration-exploitation" tradeoff means the model will sometimes recommend actions that seem suboptimal to human marketers in order to learn. Black-box nature makes it difficult to explain specific recommendations to stakeholders.
NBA Maturity Model
Most pharmaceutical companies are at Level 1 or 2 of NBA maturity. The table below defines five maturity levels and the characteristics of each, providing a roadmap for progressive capability building.
| Level | Name | Approach | Data Integration | Typical Outcome |
|---|---|---|---|---|
| 1 | Segment-Based Cadences | Static rules by HCP segment (high/medium/low prescriber) | CRM + Rx data only | Baseline engagement |
| 2 | Triggered Sequences | Behavioral triggers (email open, sample request) initiate pre-built sequences | CRM + email + Rx data | +10-15% engagement vs. Level 1 |
| 3 | Predictive Scoring | ML models predict HCP propensity and recommend channel priority | CRM + email + digital + Rx + claims | +15-25% engagement, +10-15% conversion |
| 4 | Individualized NBA | Per-HCP recommendations across channel, content, timing, and frequency | All above + external signals + real-time behavioral data | +25-35% engagement, +15-25% conversion |
| 5 | Autonomous Optimization | RL agent continuously optimizes with minimal human intervention, self-corrects | All above + closed-loop measurement + automated execution | +35-50% engagement, +25-35% conversion |
Implementation Approaches
There are three primary approaches to implementing NBA in pharmaceutical marketing, each with different tradeoffs in terms of speed, cost, and capability.
Approach 1: CRM-Native NBA
Platforms like Veeva CRM and Salesforce Health Cloud now include native NBA capabilities that leverage the data already within the CRM. Veeva's suggestion engine, for example, can recommend next actions to reps based on HCP engagement history, prescribing trends, and pre-configured business rules.
Best for: Teams at maturity Level 1-2 looking for a quick win with minimal additional investment. The CRM-native approach leverages existing data and workflows and can be implemented in weeks rather than months.
Limitations: Recommendations are limited to the data within the CRM. Digital engagement signals, webinar data, and external context are not incorporated. The recommendation logic is primarily rule-based rather than ML-driven.
Approach 2: Customer Data Platform (CDP) with NBA Module
A CDP unifies data from CRM, email, digital, events, and Rx sources into a single HCP profile and applies ML models to generate NBA recommendations. Platforms like Salesforce CDP, Adobe Real-Time CDP, and specialized pharma CDPs offer this capability.
Best for: Teams at maturity Level 2-3 who have established data integration across at least 3-4 channels and want to move from segment-based to individualized recommendations. Implementation typically takes 6-12 months.
Limitations: Requires significant data engineering work to connect all data sources to the CDP. The CDP vendor's ML models may not be optimized for pharmaceutical-specific use cases. Ongoing data quality management is essential.
Approach 3: Custom ML Pipeline
Building a custom NBA system using internal or consulting data science resources provides the highest degree of customization and control. The team designs and trains models specific to their brand's channels, HCP population, and business objectives.
Best for: Teams at maturity Level 3-4 with strong data science capabilities and a commitment to building NBA as a core competitive advantage. Implementation takes 12-18 months for the initial build, with ongoing refinement.
Limitations: Highest cost and longest timeline. Requires dedicated data science and engineering talent. Maintenance and model retraining are ongoing obligations. Risk of overfitting to historical patterns if not properly validated.
Case Example: NBA in Action
Consider a hypothetical immunology brand that implemented Level 3 NBA (Predictive Scoring) across five channels: field force, approved email, webinars, digital NPP, and eSampling. The brand had 12,000 target HCPs and a $35 million annual marketing budget.
Before NBA, the brand operated on a standard cadence: reps visited high-value HCPs monthly, medium-value HCPs quarterly; emails were sent on a biweekly schedule to all opted-in HCPs; digital ads ran continuously; webinar invitations were sent to all target HCPs. Every HCP in a segment received the same sequence regardless of individual engagement behavior.
After implementing NBA, the system generated individualized recommendations that frequently challenged the standard cadence:
- Dr. A (high-value, declining TRx): NBA recommended pausing email for 30 days and scheduling a peer-to-peer discussion focused on real-world evidence, after detecting that email opens had dropped from 35% to 8% while prescribing declined 15% quarter-over-quarter. The P2P event was triggered, Dr. A attended, and TRx recovered within two months.
- Dr. B (medium-value, no rep access): NBA detected that Dr. B was spending significant time on the brand's clinical data portal (average 12 minutes per visit, three visits per month). The recommendation was to intensify digital advertising with efficacy messaging and invite to a webinar on patient selection criteria. Dr. B attended the webinar and wrote her first prescription six weeks later.
- Dr. C (high-value, stable prescriber): NBA recommended reducing rep visit frequency from monthly to bimonthly and redirecting the saved calls to a new high-potential HCP who had just completed residency. The model calculated that Dr. C's prescribing was unlikely to decline with reduced frequency (confidence: 89%) while the new HCP had a high propensity to convert with early rep engagement.
Over the first 12 months of NBA implementation, the brand achieved a 22% increase in HCP engagement score, 17% improvement in new prescriber conversion rate, and 12% improvement in marketing ROI. These gains were achieved without increasing the total marketing budget.
Getting Started: A Practical First Step
Recommended Starting Point: If your team is at Level 1 or 2, do not attempt to build a custom ML pipeline immediately. Instead, take these three steps:
1. Audit your data readiness. Map every channel you operate and document what behavioral data you capture, where it lives, and whether it can be linked to individual HCPs. Most teams discover gaps they did not know existed.
2. Implement behavioral triggers. Move from static cadences to trigger-based sequences. Even simple triggers like "if HCP opens email about efficacy data, send follow-up email with supporting clinical evidence within 48 hours" can produce a 10-15% engagement uplift.
3. Build propensity scores. Work with your analytics team or a vendor to build a simple propensity model that predicts the likelihood of each HCP writing a new prescription in the next 90 days. Use these scores to prioritize field force call allocation and digital ad targeting. This alone typically generates a 10-15% improvement in conversion efficiency.
The journey from rule-based cadences to AI-powered NBA is not a single leap but a series of incremental steps, each building on the data and organizational capabilities established in the prior phase. The brands that will lead in HCP engagement over the next five years are not necessarily those with the largest AI budgets, but those that start building the data foundation and analytical muscles today.